KABI PHARMACIA’s DIPENTUM CONSENT DECREE REQUIRES FDA-APPROVED TRAINING PROGRAM FOR SALES REPS; JULY 30 ORDER IS FDA’s FIRST "SIGNIFICANT" DETAILING CASE